Long Unwinding

Symbol Prev OI Curr OI OI Chg (%) Curr Pr. Pr.Chg (%) Vol.chg (%)
JETAIRWAYS 6399.00 6243.00 [2.4] 604.50 [1.2] 38.7
JUBLFOOD 6219.00 6210.00 [0.1] 1112.85 [4.2] 21
Symbol Prev OI Curr OI OI Chg (%) Curr Pr. Pr.Chg (%) Vol.chg (%)
No record found.
Symbol Prev OI Curr OI OI Chg (%) Curr Pr. Pr.Chg (%) Vol.chg (%)
No record found.
FIIs trend in derivatives
Instruments Buy[Rs.Cr] Sell[Rs.Cr] Net Positions [Rs.Cr] Contracts ['000s] Value[Rs.Cr]
Index Futures 33,680.00 54,057.00 33.00 258.78 10,518.55
Index Options 260,609.00 238,707.00 260.00 1,493.47 60,433.08
Stock Futures 42,846.00 62,474.00 42.00 1,293.08 48,186.30
Stock Futures 42,766.00 42,526.00 42.00 60.64 2,238.82
News

Jaiprakash Power Ventures Q4 net loss at Rs.3528.50mn

India Infoline News Service May-28-2016

otal Income is Rs. 5746.50 million for the quarter ended March 31, 2016 where as the same was at Rs. 9875.10 million for the quarter ended March 31, 2015.

Tata Comm Q4 net loss at Rs. 2058.90mn

India Infoline News Service May-28-2016

otal Income has increased from Rs. 48804.30 million for the Quarter ended March 31, 2015 to Rs. 52394.40 million for the Quarter ended March 31, 2016.

IOB Q4 net loss at Rs.9361.90mn

India Infoline News Service May-27-2016

otal Income has decreased from Rs. 67040.30 million for the quarter ended March 31, 2015 to Rs. 61577.20 million for the quarter ended March 31, 2016.

NMDC Q4 net profit at Rs. 552.9 crore

India Infoline News Service May-27-2016

otal income has decreased from Rs. 35547.70 million for the quarter ended March 31, 2015 to Rs. 19679.40 million for the quarter ended March 31, 2016.

Oil India Q4 PAT at Rs. 4692.40 mn

India Infoline News Service May-27-2016

otal Income has decreased from Rs. 29780.10 mn for the quarter ended March 31, 2015 to Rs. 24406.40 million for the quarter ended March 31, 2016.

Enhanced liver fibrosis: A blood test for Liver Fibrosis

India Infoline News Service May-27-2016

pplication of this score to patients with chronic liver disease allows physicians to better assess fibrotic progression and can significantly reduce the number of patients requiring biopsy.